Michael Poon1, Jonathan Hwang1, Kristopher Dennis2,3, Carlo DeAngelis1, Liying Zhang1, Hans Chung1, Jordan Stinson1, Shun Wong1, Natalie Pulenzas1, Edward Chow4,5. 1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 2. Division of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada. 3. Ottawa Hospital Research Institute, Ottawa, ON, Canada. 4. Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. Edward.Chow@sunnybrook.ca. 5. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. Edward.Chow@sunnybrook.ca.
Abstract
PURPOSE: Nausea and vomiting are common side effects from radiotherapy that can interfere with gastrointestinal (GI) cancer patients' quality of life (QOL). This study described the subjective experience of patients with radiation-induced nausea and vomiting (RINV) and its relation to QOL. METHODS: Forty-eight patients treated with abdominal radiotherapy alone or with concomitant chemoradiotherapy were followed in a prospective study. All episodes of nausea, vomiting, and antiemetic use were recorded daily for the treatment period and the week following completion of therapy. QOL was assessed weekly using the Functional Living Index-Emesis QOL Tool (FLIE) and the EORTC QLQ-C30 core questionnaire (C30). RESULTS: In total, 351 episodes of nausea severity, duration, onset time, and 154 outcomes of vomiting onset times and contents were documented. The median nausea severity experienced per episode was 5 (on a scale from 1 to 10), and the most common durations of nausea were 30 min or less and constant nausea all day and night. The most common location of nausea was the abdomen. Longer nausea duration, great nausea severities, and the location of nausea experienced had significant adverse relationships to multiple QOL items on both the FLIE and the C30. In addition, the onset timing and number of vomiting episodes were related to the majority of all FLIE and QOL scores. CONCLUSION: Patient's subjective experiences of RINV directly correlated to the worsening of QOL outcomes. The identification and amelioration of these RINV experiences could improve QOL.
PURPOSE:Nausea and vomiting are common side effects from radiotherapy that can interfere with gastrointestinal (GI) cancerpatients' quality of life (QOL). This study described the subjective experience of patients with radiation-induced nausea and vomiting (RINV) and its relation to QOL. METHODS: Forty-eight patients treated with abdominal radiotherapy alone or with concomitant chemoradiotherapy were followed in a prospective study. All episodes of nausea, vomiting, and antiemetic use were recorded daily for the treatment period and the week following completion of therapy. QOL was assessed weekly using the Functional Living Index-Emesis QOL Tool (FLIE) and the EORTC QLQ-C30 core questionnaire (C30). RESULTS: In total, 351 episodes of nausea severity, duration, onset time, and 154 outcomes of vomiting onset times and contents were documented. The median nausea severity experienced per episode was 5 (on a scale from 1 to 10), and the most common durations of nausea were 30 min or less and constant nausea all day and night. The most common location of nausea was the abdomen. Longer nausea duration, great nausea severities, and the location of nausea experienced had significant adverse relationships to multiple QOL items on both the FLIE and the C30. In addition, the onset timing and number of vomiting episodes were related to the majority of all FLIE and QOL scores. CONCLUSION:Patient's subjective experiences of RINV directly correlated to the worsening of QOL outcomes. The identification and amelioration of these RINV experiences could improve QOL.
Entities:
Keywords:
Patient-reported outcomes; Radiotherapy-induced emesis; Radiotherapy-induced nausea and vomiting
Authors: Kristopher Dennis; Liying Zhang; Stephen Lutz; Angela van Baardwijk; Yvette van der Linden; Tanya Holt; Palmira Foro Arnalot; Jean-Léon Lagrange; Ernesto Maranzano; Rico Liu; Kam-Hung Wong; Lea-Choung Wong; Vassilios Vassiliou; Benjamin W Corn; Carlo De Angelis; Lori Holden; C Shun Wong; Edward Chow Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-15 Impact factor: 7.038
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: Ernesto Maranzano; Verena De Angelis; Stefano Pergolizzi; Marco Lupattelli; Paolo Frata; Stefano Spagnesi; Maria Luisa Frisio; Giovanni Mandoliti; Giuseppe Malinverni; Fabio Trippa; Letizia Fabbietti; Salvatore Parisi; Annamaria Di Palma; Pietro De Vecchi; Costantino De Renzis; Celestino Giorgetti; Tiziano Bergami; Roberto Orecchia; Maurizio Portaluri; Marco Signor; Davide Di Gennaro Journal: Radiother Oncol Date: 2009-12-04 Impact factor: 6.280
Authors: Arash Naeim; Sydney M Dy; Karl A Lorenz; Homayoon Sanati; Anne Walling; Steven M Asch Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson Journal: Support Care Cancer Date: 2008-06-05 Impact factor: 3.603